Orbimed Advisors Llc Sells 115,844 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Posted by Francis Steltz on Jul 2nd, 2026

Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) Director Orbimed Advisors Llc sold 115,844 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares in the company, valued at $116,292,403.50. This represents a 4.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

On Wednesday, May 27th, Orbimed Advisors Llc sold 101 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total value of $4,493.49.
On Monday, May 11th, Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58.
On Friday, May 8th, Orbimed Advisors Llc sold 59,767 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total value of $2,664,412.86.
On Thursday, May 7th, Orbimed Advisors Llc sold 48,546 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.61, for a total transaction of $2,165,637.06.
On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96.
On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.68, for a total transaction of $2,341,097.96.
On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total transaction of $10,287,918.04.
On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32.
On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.51, for a total transaction of $2,128,201.14.

Sionna Therapeutics Trading Up 5.6%

Shares of Sionna Therapeutics stock traded up $2.35 on Thursday, hitting $43.99. 328,677 shares of the company traded hands, compared to its average volume of 364,115. The firm’s 50-day simple moving average is $39.79 and its 200 day simple moving average is $39.49. The company has a market cap of $1.99 billion, a P/E ratio of -22.79 and a beta of 1.33. Sionna Therapeutics, Inc. has a 12-month low of $16.38 and a 12-month high of $48.44.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Analysts predict that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on SION shares. Stifel Nicolaus upped their price objective on Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, May 18th. Freedom Capital cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday, May 8th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $63.00 target price on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Finally, JonesTrading increased their price target on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $53.22.

Get Our Latest Stock Analysis on SION

Institutional Investors Weigh In On Sionna Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new stake in Sionna Therapeutics in the 3rd quarter worth $30,000. BNP Paribas Financial Markets bought a new position in shares of Sionna Therapeutics during the second quarter valued at about $31,000. GF Fund Management CO. LTD. bought a new position in shares of Sionna Therapeutics during the fourth quarter valued at about $36,000. Balyasny Asset Management L.P. purchased a new stake in shares of Sionna Therapeutics during the fourth quarter worth about $58,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Sionna Therapeutics during the fourth quarter worth about $89,000.

About Sionna Therapeutics

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.